You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Biochemistry & Bioanalytical
Allergic Conjunctivitis
Allergic conjunctivitis is an increasingly prevalent ocular allergy and is classified as a hypersensitivity disorder that affects the lid, conjunctiva, and cornea1. Mast cells are highly populated in the choroid, subconjunctival and episcleral tissues, and the degranulation of these cells is largely responsible for the immediate hypersensitivity reactions seen in allergic conjunctivitis disease pathology2.
The experts at GD3 replicate this disease pathology through topical administration of Compound 48/80, which is a mast cell degranulating agent3. Following successful induction, we are enabled to confirm and longitudinally follow disease status and understand the effect that various types of therapeutic candidates have on disease pathology.
| Animal Species | Rabbit |
| Method of Induction | Topical administration of Compound 48/80 |
| Follow up Period | 24 hrs. to 1 week |
| Route of intervention | Topical (ocular), IVT, systemic |
| Readouts |
|
Reference:
- 1. Benditt and Lagunoff, 1964
- 2. Hogan, Alvarado and Weddell, 1971).
- 3. https://pubmed.ncbi.nlm.nih.gov/6838424/
Learn more about